Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas. Show more

6801 N. Capital of Texas Highway, Austin, TX, 78731, United States

Biotechnology

Healthcare

Market Cap

115M

52 Wk Range

$1.15 - $4.98

Previous Close

$2.38

Open

$2.38

Volume

N/A

Day Range

$2.38 - $2.38

Enterprise Value

-7.582M

Cash

95.5M

Avg Qtr Burn

-9.748M

Insider Ownership

12.79%

Institutional Own.

28.98%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Simufilam Details Tuberous Sclerosis Complex (TSC)-related epilepsy	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Simufilam (PTI-125) Details Alzheimer's disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.